Oslo University Hospital HF — Sponsor Intelligence | 75 EU Trials

Filter these 75 trials by condition, phase, country and more.

Open in Search →

75 Registered trials

35 Recruiting

28 Completed trials

20 Countries active

142 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 12 Phase II/III: 4 Phase II: 30 Phase I/II: 5 Phase III/IV: 1 Phase IV: 18 Phase I: 2 Phase I (Other): 2 Phase I (FiH): 1

Oversight events:

4 serious breaches 11 temporary halts 4 urgent safety measures across 7 trials

View oversight register →

100%

28 of 28 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioblastoma 3 Glioblastoma multiforme 2 Ischaemic stroke 2 Heart disease congenital 1 Pleural mesothelioma malignant 1 Aortic stenosis 1 Follicle centre lymphoma follicular grade I II III 1 Mitral valve prolapse 1 Colorectal cancer metastatic 1 Malignant melanoma stage III 1 Soft tissue sarcoma 1 Breast cancer 1

Top IMPs

SODIUM CHLORIDE 9 DEXAMETHASONE 4 MYCOPHENOLATE MOFETIL 3 NIVOLUMAB 3 TACROLIMUS 3 ATEZOLIZUMAB 2 BEVACIZUMAB 2 DABRAFENIB 2 FLOXURIDINE 2 GEMCITABINE 2 NEPAFENAC 2 OXYTOCIN SYNTHETIC 2

All trials — page 3

75 total

DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves… Ended

2022-502640-12-01 Phase I/II 4 countries
RElapse from Mrd Negativity As iNdication for Treatment Ended

2023-510215-18-00 Phase II/III 2 countries BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE
Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomis… Ended

2023-510212-39-00 Phase III/IV 1 country
Pyridoxine in primary sclerosing cholangitis Ended

2023-505155-47-00 Phase II 1 country
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Phase II 4 countries MOSUNETUZUMAB
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9 Ended

2022-500706-18-01 Phase I 1 country
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed K… Ended

2022-502275-39-00 Phase I/II 1 country
A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine brom… Ended

2024-511848-55-00 Phase III 1 country HYOSCINE BUTYLBROMIDE; SODIUM CHLORIDE; SODIUM HYDROGEN CARBONATE
DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients Ended

2023-506486-60-01 Phase III 3 countries
The REST (Replacing Steroids in the transplant ineligible) study. Ended

2023-510194-34-00 Phase II 2 countries
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Phase II/III 4 countries ALREFIMOTIDE, RILETAMOTIDE, TAPDERIMOTIDE; IPILIMUMAB; NIVOLUMAB; SARGRAMOSTIM
Imaging Perfusion Restrictions from Extracellular Solid Stress - An open-label losartan study Ended

2023-507575-22-00 Phase II 1 country LOSARTAN POTASSIUM
Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden Halted

2024-512397-95-00 Phase II 1 country FLOXURIDINE
Propofol injection pain in healthy adult participants Ended

2024-514307-34-01 Phase II 1 country PROPOFOL
Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept Ended

2025-521800-22-00 Phase IV 1 country MYCOPHENOLATE MOFETIL; TACROLIMUS
Rebound pain after volar plate surgery in infraclavicular brachial plexus block with ropivacaine 3.75 mg/ml compared with 7.5 mg/ml. A prosp… Ended

2024-514795-41-00 Phase IV 1 country DEXAMETHASONE; ETORICOXIB; OXYCODONE HYDROCHLORIDE; PARACETAMOL; ROPIVACAINE HYD…
CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS Ended

2024-515164-30-00 Phase IV 1 country COLECALCIFEROL, CALCIUM; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS
Acetated Ringer´s solution in experimental hypovolemia Ended

2023-503946-30-00 Phase IV 1 country MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHL…
Treatment of Keratolytic Winter Erythema in adults with systemic nitroxoline Ended

2022-501726-38-00 Phase II 1 country
Theophylline Effects in the Fontan Circulation Ended

2022-500301-41-00 Phase II 1 country THEOPHYLLINE
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 Phase II 10 countries BEMCENTINIB
Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosis Ended

2023-510211-20-00 Phase III 1 country
Zoledronate Early to Hip Fractures Patients – safe and effective? A Randomized controlled double-blinded treatment strategy trial on Zoledro… Ended

2023-510198-32-00 Phase IV 1 country
PARASTOP - Paracetamol with Strong Opioids Ended

2024-515012-53-00 Phase III 1 country PARACETAMOL

Showing 49–72 of 75 trials

← All sponsors A–Z